Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.79 |
| ▸ | HTR1A | P08908 | 5/20 | 0.79 |
| ▸ | HTR7 | P34969 | 3/20 | 0.79 |
| ▸ | DRD3 | P35462 | 3/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.79 |
| ▸ | HTR1D | P28221 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | HTR1B | P28222 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | HTR2C | P28335 | 1/20 | 0.79 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.79 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | HTR5A | P47898 | 1/20 | 0.79 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.77 |
| ▸ | DRD1 | P21728 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6820459 | 0.90 | HTR1A (0.65) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL8158925 | 0.90 | HTR1A (0.65) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL7023248 | 0.90 | HTR1A (0.65) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL3748260 | 0.90 | HTR1A (0.74) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL13042650 | 0.90 | HTR1A (0.74) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| SCHEMBL2023821 | 0.89 | DRD2 (0.83) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| Bromide SCHEMBL4750964 | 0.89 | BLM (0.66) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| 8-Oh-Dpat SCHEMBL1682330 | 0.89 | HTR1A (1.00) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| 8-Oh-Dpat SCHEMBL1682347 | 0.89 | HTR1A (1.00) | DRD2HTR1AHTR7DRD3CYP1A2 | |
| 8-Oh-Dpat SCHEMBL496783 | 0.89 | HTR1A (1.00) | DRD2HTR1AHTR7DRD3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7829587-B2 | Substituted 2-aminotetralin derivatives as selective alpha 2B agonist | ALLERGAN, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-7655599-B2 | Formulation comprising 1-40 w/w % fluoxastrobin, 5-30 w/w % emulsifier, penetration promoter, and optionally additives, and 20-70 w/w % gamma-butyrolactone and 5-20 w/w % of at least one ethylene diamine alkoxylate, which acts as an emulsion stabilizer or a crystallization inhibitor | BAYER CROPSCIENCE AG (DE) | 2010-02-02 | — | — | US | disclosed |
| WO-2009089284-A2 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089284-A2 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ALLERGAN, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20060183639-A1 | Agrochemical formulations | BAYER CROPSCIENCE AG (DE) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183639-A1 | Agrochemical formulations | DDT, ALKBH3, DDC | DRD2 2172/4885HTR1A 3651/4885HTR7 1854/4885 |
| US-20090176845-A1 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST | ADRA2B, ADRA1B, ADRB2 | DRD2 310/4885HTR1A 17/4885HTR7 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.